Skip to content

Inspection Record

Snap Diagnostics, LLC. — FDA 483 Findings

US FDAInspected 2026-02-13Published 2026-10-20 3 findingsOther quality system

Inspectors Shuana H XiongThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Corrective action was not adequately taken to eliminate the cause of nonconformities in order to prevent recurrence.

2Other quality system

Procedures to define the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product were not adequately documented.

3Other quality system

One or more processes for risk management in product realization have not been adequately documented.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Snap Diagnostics, LLC. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.